Charles River Laboratories Intl. Inc (CRL) Shares Bought by Zurcher Kantonalbank Zurich Cantonalbank

Zurcher Kantonalbank Zurich Cantonalbank lifted its position in Charles River Laboratories Intl. Inc (NYSE:CRL) by 43.4% in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 2,568 shares of the medical research company’s stock after acquiring an additional 777 shares during the quarter. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Charles River Laboratories Intl. were worth $281,000 as of its most recent filing with the SEC.

Other large investors have also recently modified their holdings of the company. Jane Street Group LLC purchased a new stake in shares of Charles River Laboratories Intl. in the 3rd quarter valued at approximately $261,000. Legal & General Group Plc lifted its position in shares of Charles River Laboratories Intl. by 15.8% in the 3rd quarter. Legal & General Group Plc now owns 46,119 shares of the medical research company’s stock valued at $4,982,000 after acquiring an additional 6,287 shares in the last quarter. State Street Corp lifted its position in shares of Charles River Laboratories Intl. by 2.3% in the 2nd quarter. State Street Corp now owns 1,268,308 shares of the medical research company’s stock valued at $128,288,000 after acquiring an additional 28,365 shares in the last quarter. Ameriprise Financial Inc. lifted its position in shares of Charles River Laboratories Intl. by 7.5% in the 3rd quarter. Ameriprise Financial Inc. now owns 185,847 shares of the medical research company’s stock valued at $20,076,000 after acquiring an additional 12,903 shares in the last quarter. Finally, Shaker Investments LLC OH lifted its position in shares of Charles River Laboratories Intl. by 25.6% in the 3rd quarter. Shaker Investments LLC OH now owns 8,040 shares of the medical research company’s stock valued at $868,000 after acquiring an additional 1,640 shares in the last quarter. Institutional investors and hedge funds own 99.03% of the company’s stock.

In other news, Director C Richard Reese sold 10,227 shares of the stock in a transaction on Wednesday, December 6th. The shares were sold at an average price of $102.40, for a total transaction of $1,047,244.80. Following the transaction, the director now owns 51,444 shares in the company, valued at approximately $5,267,865.60. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Robert J. Bertolini sold 3,609 shares of the stock in a transaction on Tuesday, January 2nd. The stock was sold at an average price of $110.22, for a total transaction of $397,783.98. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 198,545 shares of company stock worth $2,956,233. 2.20% of the stock is currently owned by company insiders.

Shares of Charles River Laboratories Intl. Inc (NYSE CRL) opened at $108.11 on Monday. Charles River Laboratories Intl. Inc has a 12-month low of $86.25 and a 12-month high of $119.05. The company has a debt-to-equity ratio of 1.06, a current ratio of 1.78 and a quick ratio of 1.54. The stock has a market cap of $5,127.54, a P/E ratio of 42.56, a price-to-earnings-growth ratio of 1.51 and a beta of 0.74.

Charles River Laboratories Intl. (NYSE:CRL) last announced its quarterly earnings results on Tuesday, February 13th. The medical research company reported $1.40 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.26 by $0.14. Charles River Laboratories Intl. had a net margin of 6.64% and a return on equity of 26.14%. The company had revenue of $478.50 million for the quarter, compared to analyst estimates of $475.02 million. During the same quarter in the prior year, the business posted $1.21 EPS. Charles River Laboratories Intl.’s quarterly revenue was up 2.5% on a year-over-year basis. equities analysts expect that Charles River Laboratories Intl. Inc will post 5.77 earnings per share for the current year.

Several equities research analysts recently commented on the stock. Royal Bank of Canada set a $116.00 price target on shares of Charles River Laboratories Intl. and gave the company a “hold” rating in a research report on Tuesday, February 13th. SunTrust Banks upgraded shares of Charles River Laboratories Intl. from a “hold” rating to a “buy” rating and increased their target price for the stock from $107.66 to $125.00 in a research report on Wednesday, February 14th. JPMorgan Chase & Co. increased their target price on shares of Charles River Laboratories Intl. from $110.00 to $120.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 14th. TheStreet downgraded shares of Charles River Laboratories Intl. from an “a-” rating to a “c+” rating in a research report on Tuesday, February 13th. Finally, Barclays reiterated a “hold” rating and issued a $110.00 target price on shares of Charles River Laboratories Intl. in a research report on Friday. Seven research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. The company has an average rating of “Buy” and a consensus price target of $118.08.

TRADEMARK VIOLATION WARNING: “Charles River Laboratories Intl. Inc (CRL) Shares Bought by Zurcher Kantonalbank Zurich Cantonalbank” was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece on another website, it was illegally stolen and reposted in violation of US and international copyright & trademark laws. The legal version of this piece can be accessed at https://www.dispatchtribunal.com/2018/02/19/charles-river-laboratories-intl-inc-crl-shares-bought-by-zurcher-kantonalbank-zurich-cantonalbank.html.

About Charles River Laboratories Intl.

Charles River Laboratories International, Inc is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development.

Want to see what other hedge funds are holding CRL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Charles River Laboratories Intl. Inc (NYSE:CRL).

Institutional Ownership by Quarter for Charles River Laboratories Intl. (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories Intl. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories Intl. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply